Menostar is a drug owned by Bayer Healthcare Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 21, 2017. Details of Menostar's patents and their expiration are given in the table below.
Get the complete list right in your inbox!
Drug Patent Number
Drug Patent Title
Drug Patent Expiry
Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet,
capsules, liquids etc).
Methods for treating postmenopausal women using ultra-low doses of estrogen
Nov, 2017
(7 years ago)
Expired
Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.
Get the exclusive patent insights now. Don't be the last to know.
US patents provide insights into the exclusivity only within the United States, but Menostar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Menostar's family patents as well as insights into ongoing legal events on those patents.
Menostar's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Generic Launch
Generic Release Date:
Menostar's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 21, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Menostar Generic API suppliers:
Estradiol is the generic name for the brand Menostar.
25 different companies have already filed for the generic of Menostar, with Mylan Technologies having the maximum number of approved applications.
Check out the entire list of companies who have already received approval for Menostar's generic
Alternative Brands for Menostar
Menostar which is used for preventing postmenopausal osteoporosis., has several other brand drugs in the same treatment categoryand using the same active ingredient (Estradiol).
Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
used for management of menopausal symptoms and prevention of osteoporosis.
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Estradiol. Given below is the list of those drugs and companies owning them.
Menostar is a drug owned by Bayer Healthcare Pharmaceuticals Inc. It is used for preventing postmenopausal osteoporosis. Menostar uses Estradiol as an active ingredient. Menostar was launched by Bayer Hlthcare in 2004.
Approval Date:
Menostar was approved by FDA for market use on 08 June, 2004.
